Furthermore, no significant difference in Chi3L1 levels was observed between progressive MS and RRMS patients, neither during relapse phases, suggesting that it could serve as an outcome biomarker for all MS phenotypes. The gene discussed is CHI3L1; the disease is myeloid sarcoma.